Trial Search Results
Diagnostic and Prognostic Biomarkers for High-impact Chronic Pain: Development and Validation
To identify diagnostic and prognostic biomarker signatures of recovery versus having persisting high-impact chronic pain and functional disability in adults with Chronic Musculoskeletal Pain.
Stanford is currently accepting patients for this trial.
Collaborator: National Institute of Neurological Disorders and Stroke (NINDS)
- 1) Inclusion criteria: Adults (18-80 years; ~64% female expected based on clinic
distribution) with chronic MSP as categorized by the World Health Organization (WHO).
- 1) Chronic musculoskeletal pain (MSP) explained by inflammatory disease (e.g.,
rheumatoid arthritis, lupus) or CP with a primary diagnosis other than chronic MSP
(e.g., neuropathic pain), (2) significant cognitive impairment, (3) MRI
contraindication, (4) medical or psychiatric problems interfering with the study, (5)
current medicolegal factors (e.g., open disability claim), (6) plans for surgery
during the study, (7) pregnancy and (8) Children under the age of 18 will not be
included in the study.
Ages Eligible for Study
18 Years - 80 Years
Genders Eligible for Study